

To: **The Honorable Joseph Biden**
President of the United States

The Honorable Xavier Becerra
Secretary of Health and Human Services

The Honorable Nancy Pelosi
Speaker

The Honorable Kevin McCarthy
House Republican Leader

The Honorable Chuck Schumer
Senate Majority Leader

The Honorable Mitch McConnell
Senate Republican Leader

Dear President Biden, Secretary Becerra, Speaker Pelosi, Majority Leader Schumer, Leader McCarthy, Leader McConnell, America's Lawmakers, Patient Advocates, and Fellow Americans:

We lead, fund, and count on the many small biotechnology companies that develop medicines for diseases* that lack sufficient treatments and cause considerable suffering. The companies led by the executives among us employ 22,411 people in the US and collectively invest over \$16.9 billion/year in search of breakthroughs. We are currently testing 373 new and potentially life changing drug candidates in clinical trials, some of which build upon foundational NIH-funded research led by the academic researchers among us. The investors among us work at firms managing over \$183 billion of life science-focused capital that comes primarily from pension funds, families, universities, non-profits, and others who invest in drug development. Many of us are also patients and patient advocates, with loved ones who suffer from difficult diseases in need of better treatment options. We have dedicated ourselves to that effort.

Collectively we come together to defeat disease. Each drug in development is a complex, time consuming, and expensive scientific and medical undertaking. Most of the time we lose the battle. But we persist because the few projects that succeed will forever improve human health.

Our industry invests over \$160 billion in R&D each year. In the past decade it has created vaccines and treatments for Covid-19, treatments for cystic fibrosis and sickle cell disease, and cures for several cancers and hepatitis C. These successes are just a few examples of the many significant advances we are driving. Our efforts are reducing the burden and threat of diseases across the USA and around the globe.

It has become clear that we must also help our lawmakers understand the basic economic framework that inspires companies and investors to take the financial risk required to create new medicines. Called to action by the justifiable outrage of patients who cannot afford their out-of-pocket costs, some lawmakers have misdiagnosed the problem. They believe drug companies charge too much for their products. In response, they are proposing to enact laws that not only fall short of making drugs affordable to all patients but also defund our efforts to create better ones.

The Right Goal

To be clear, we are concerned about the high and rising out-of-pocket costs that have made our medicines increasingly unaffordable to many patients. We, too, call for a solution to affordability. We don't invent drugs to have them placed out of the reach of people who need them.

Insurance makes it possible for Americans to afford today's medicines and collectively invest in tomorrow's, as is captured in [this short video](#). To solve the problem of affordability for patients, we must lower the amount that insurance plans can make patients pay out-of-pocket, redefining proper insurance by law, just as policymakers have appropriately outlawed discrimination on the basis of pre-existing conditions.

The Wrong Policy

Instead, Congress is considering allowing the government to dictate the price that a company may charge for a novel drug with the threat of ruining the company financially with a 95% tax should the company refuse to accept the government's price.

Such draconian measures would immediately halt private funding of drug discovery and development. As an industry, we would no longer be able to infer what insurance plans might value and pay tomorrow from what they value and pay today, which is the premise of a market economy. Unpredictable government-dictated prices would supplant the current market-based framework that inspires biomedical R&D investment.

The investors among us would have to shift our investments toward areas still governed by markets, such as technology and consumer goods. Those companies with drug candidates in development would fail to raise more capital, making it pointless for them to spend existing dollars on ongoing research. The loss of hundreds of thousands of well-paying jobs would be swift, though it may take longer for the public to sense the loss of future treatments and cures.

Some may think NIH funding will be sufficient to fund continued R&D. The NIH is a crucial funder of the basic research that provides the ideas for what kinds of drugs might be possible.

Translating those ideas into actual medicines is almost entirely driven by the private sector and makes all that basic research worth funding in the first place. Some of us signing this letter are NIH funded academic researchers whose discoveries have had significant patient impact, and we affirm that the private sector has been and will continue to be essential for turning our ideas into medicines. The NIH and industry are parts [of one whole ecosystem](#), not a replacement for one another.

What's in a Word?

Successful negotiations result in market-based prices based on competing alternatives – this negotiation already takes place between drug manufacturers and insurance companies, resulting in an average 50% reduction from drugs' list prices to their net prices.

True negotiation requires that both parties can walk away from the table. True negotiation is acceptable to all of us and spurs us to compete. True negotiation means that even if we don't get to the market first, our second and third place drugs can still secure some market share by competing on price.

The proposed introduction of a 95% tax penalty would allow The Center for Medicare and Medicaid Services (CMS) to simply dictate any drug's price. This is not true negotiation.

As proposed, the government would be able to keep a company from walking away from an unacceptably low price. This gives the American public the impression that they can have any drug that's been invented for any price, however low. Overlooked in that bargain is that investors and companies will stop investing in new programs, and we'll give up the medicines that haven't been invented yet.

Congress may not intend to dictate the price for every drug. But dictating the price of drugs covered by Medicare would defund R&D for diseases of aging, including Alzheimer's, osteoporosis, and cancer. Dictating prices for medicines priced above a certain threshold would defund R&D for rare diseases. Dictating prices for medicines that generate the most total revenue would defund R&D for our most difficult diseases, since those are the ones that require greater expected revenues to incentivize substantial R&D investment.

Dictating prices for drugs deemed less "valuable" to society sounds tempting, until one realizes that the math for estimating a drug's value is so nascent, imprecise, and controversial that it's easily biased to reflect the preferences of the practitioner. For example, a recent business plan competition demonstrated that [not a single project would be fundable](#) if future products could only be priced in accordance with the [over-simplified math](#) used in the UK and Canada. Furthermore, there is mounting evidence from health economics research that medicines offer greater societal value than is reflected by their prices.

Better Solutions

We already have a functioning mechanism to drive down drug prices: drugs go generic. Because drugs go generic, what America spends on drugs has remained at roughly 10% of healthcare spending for decades, yet we have so many more effective and safer medicines today than in the 1970s.

Hospitals, long-term care facilities, and medical procedures do not go generic; those costs have only been climbing. We can keep ourselves from having to rely as much on hospitals in the future by inventing better medicines, which will then go generic. Society saves money, and we all lead healthier lives.

Preserving market-based incentives for drug R&D is how we get the medicines to achieve this goal. Heart transplants were first performed in 1967 and climbed in price by over 2,000% to cost \$1.4 million today. The heart failure drug amiloride helps avert the need for transplants and was approved in 1967; today it costs 26 cents/pill. We haven't solved heart failure, but we're working on it. So, there's hope for the people who need better heart failure medicines, but that hope requires continued investment in R&D.

America, and specifically CMS, can still save on drugs without sacrificing future treatments, cures, and vaccines. Certain drugs do not go generic even after their patents have expired, and CMS could save money by solving that particular market failure. Doing so would not reduce R&D incentives. [Members of industry](#) and others have proposed [a specific, actionable framework](#) for how this could work.

Averting A Costly Error

It's true that replacing market-based pricing with non-market government-dictated prices will reduce healthcare spending in the short run (the Congressional Budget Office, which helps lawmakers determine what legislation may cost or save the government, uses a 10-year timeframe). But without new medicines, this policy will condemn America to spend far more on managing diseases in hospitals and long-term care facilities for decades to come.

The worst part is that it will take a long time to realize that we're not making progress like we used to. For example, antibiotic R&D has historically suffered from low investment incentives because the prices of antibiotics are so low. Today, we urgently need new antibiotics to combat the rise of resistant bacterial infections, but it will take years to remedy this gap in R&D even with proper incentives and funding. It's hard to appreciate what we don't have until we need it.

The advocates among us know this acutely, having worked with so many patients struggling to make it to the next breakthrough.

Where there are market failures, we should fix them. All drugs should go generic without undue delay. Americans should not suffer because their insurance burdens them with unaffordable out-of-pocket costs, whether they get their drugs through Medicare, their employer insurance, or on the public exchanges. Patients and policyholders should benefit from the savings insurers negotiate with drug companies, and drugs covered under Medicare Part B should be subject to the same competitive

market forces as those covered by Part D. Lawmakers should focus on these important, achievable, and bipartisan reforms for the benefit of all Americans.

In the meantime, the term “negotiation” must not be redefined to encompass the government dictating a price under threat of financial ruin. Were such a law to pass, capital would be immediately redirected away from biomedical R&D, with an immediate effect on biotechnology jobs and longer-term harm to patients and our national budget and security.

Some observers of the drug development ecosystem who propose different theories and models of how it works might contradict us. But the executives and investors among us write not as observers of biotech’s economic framework but as its actual elements and conductors; capital and incentives flow through our funds and our companies like electricity through a circuit. It is evident to us that replacing true negotiation with dictated prices would defund R&D, like flipping off a light switch.

Sincerely,

Peter Kolchinsky, Aoife Brennan, Alex Karnal, Jeremy Levin, Laura Shawver, Daphne Zohar, and Signatories to this Statement, listed below**:

Peter Kolchinsky, PhD
RA Capital Management, LP
Boston, MA

Aoife Brennan, MB, BCh, BAO, MRCPI
Synlogic Therapeutics
Cambridge, MA

Alex Karnal
Braidwell Management
New York City, NY

Jeremy Levin, D.Phil, MB BChir
Ovid Therapeutics
New York City, NY

Laura Shawver, PhD
Silverback Therapeutics
Seattle, WA

Daphne Zohar
PureTech Health
Boston, MA

Robert Langer, ScD
MIT
Cambridge, MA

Paul Hastings
Nkarta Therapeutics
South San Francisco, CA

Bob Nelsen
ARCH Venture
Seattle, WA

Jean Francois Formela, MD
Atlas Venture
Boston, MA

John Maraganore, PhD
Alynlam Pharmaceuticals
Cambridge, MA

Gunnar Esiason, MBA
Boomer Esiason Foundation
New York, New York

Ted W. Love, MD
Global Blood Therapeutics
South San Francisco, CA

Brook Byers
Kleiner Perkins
Menlo Park, CA

Siddhartha Mukherjee, MD Dphil
Columbia University
New York, NY

Arjun Goyal, MD
Vida Ventures
Boston, MA

Wendye Robbins
Blade Therapeutics
South San Francisco, CA

Ron Cohen, MD
Acorda Therapeutics
Ardsley, NY

Corey S. Goodman, PhD
venBio Partners
San Francisco, CA

Mark Murcko, PhD
Dewpoint Therapeutics
Boston, MA

Kush M Parmar, MD, PhD
5AM Ventures
Boston, MA

Akiko Iwasaki
Yale University
New Haven, CT

Nina Kjellson
Canaan Partners
San Francisco, CA

Rajeev Shah
RA Capital Management, LP
Boston, MA

J. Tyler Martin, MD
Adjuvance Technologies
Lincoln, NE

Robert Ang
Vor BioPharma
Cambridge, MA

D.A. Wallach
Time BioVentures
Los Angeles, CA

Jeffrey L Cleland, PhD
Ashvattha Therapeutics
Redwood City, CA

Jake Becraft, PhD
Strand Therapeutics Inc
Cambridge, MA

Peter A. Thompson, MD
OrbiMed Advisors
New York, NY

James McArthur, PhD
PepGen Inc
Cambridge, MA

Robert D. Schultz
Satsuma Pharmaceuticals, Inc.
Durham, NC

Jeffrey Bird, MD, PhD
Bluebird Ventures
Palo Alto, California

Troy Wilson, PhD, JD
Kura Oncology
San Diego, CA

Peter Bisgaard
Pivotal Life Sciences
San Francisco, CA

John A. Scarlett, MD
Geron Corporation
Foster City, CA

Todd Harris
Tyra Biosciences
Carlsbad, CA

Paul Bolno, MD
Wave Life Sciences
Cambridge, MA

Cedric Francois, MD, PhD
Apellis Pharmaceuticals, Inc.
Waltham, MA

Marc de Garidel
CinCor
Boston, MA

Andreas Wicki
HBM Healthcare Investments AG
Zug, Switzerland

Jill C. Milne, PhD
Catabasis Pharmaceuticals
Boston, MA

Jeffrey A. Leerink
SVB Leerink
Boston, MA

Jay Venkatesan, MD
Angion
Uniondale, NY

Nicholas Oo
Invus
New York, NY

Stephen J. Hoffman, PhD, MD
Apic-Bio, Inc.
Cambridge, MA

David A. Katz, PhD
Sparrow Pharmaceuticals
Portland, OR

Joseph Healey
HealthCor Management
New York, NY

Joshua Resnick, MD
RA Capital
Boston, MA

Blake Wise
Novome Biotechnologies
South San Francisco, CA

Ashley Dombkowski, PhD
Alladapt Immunotherapeutics, Inc
Menlo Park, CA

Michael R. Hayden, MBChB, PhD
Prilenia Therapeutics
Herzaliya, Israel

Timothy M Shannon, MD
Canaan Partners
Westport, CT

Nancy A. Thornberry
Kallyope
New York, NY

Frank Watanabe
Arcutis Biotherapeutics
Westlake Village, CA

Ken Drazan
Arsenal Biosciences
South San Francisco, CA

Jon Edwards, PhD
Red Tree Venture Capital
Menlo Park, CA

Yishai Zohar
Gelesis Inc
Boston, MA

Sadik H. Kassim, PhD
Vor Bio
Cambridge, MA

Eric Dube, PhD
Travere Therapeutics
San Diego, CA

Scott Clarke
Ambagon Therapeutics
San Francisco, CA

Stephen Dilly M.B.B.S., Ph.D
Sierra Oncology
San Francisco, CA

Jeff Albers
Blueprint Medicines
Cambridge, MA

David-Alexandre C. Gros, MD
Eledon Pharmaceuticals
Irvine, CA

Alain D. Baron, MD
Escient Pharmaceuticals
San Diego, CA

Amit D. Munshi
Arena Pharmaceuticals Inc
San Diego, CA

John Kollins
Satsuma Pharmaceuticals, Inc.
South San Francisco, CA

Amy Burroughs
Cleave Therapeutics
San Francisco, CA

Sarah Boyce
Avidity Bioscience
San Diego, CA

David Sable, MD
Special Situations Life Sciences Fund
New York, NY

Sean Jeffries, PhD
Design Therapeutics
Carlsbad, CA

Dr. Vipin Garg
Altimune, Inc.
Gaithersburg, MD

James A. Geraghty
Fulcrum Therapeutics
Cambridge, MA

Gregory J. Flesher
Reneo Pharmaceuticals, Inc.
Irvine, CA

Andy Schwab
5AM Ventures
San Francisco, CA

Cris Montero, PhD
RA Capital Management, LP
Boston, MA

Agustin Mohedas, PhD
Janus Henderson Investors
Denver, CO

Larry Feinberg
Oracle Partners L.P.
Greenwich, CT

Andrew N. Schiff, MD
Aisling Capital
New York, NY

Melinssa McCracken, PhD
Nextech Invest
Boston, MA

Ed Mascioli
EMMD LLC
Boston, MA

Alex Virgilio
Asymmetry Capital Management
San Francisco, CA

Brian Halak, PhD
Domain Associates
Princeton, NJ

Nassim Usman, PhD
Catalyst Biosciences
South San Francisco, CA

Jak Knowles
Affini-T Therapeutics
Boston, MA

Dan Becker, MD, PhD
Access Biotechnology
New York, NY

Doug Crawford
Mission BioCapital
San Francisco, CA

Matt Eckler
Arrowmark Partners
Denver, CO

Vikram Khanna
Ikarian Capital
Dallas, TX

Todd Foley
MPM Capital
Cambridge, MA

Kenneth I. Moch
Euclidean Life Science Advisors
Chapel Hill, NC

Michael Broxson
Q32 Bio
Cambridge, MA

Arthur Tzianabos, PhD
Homology Medicines
Bedford, MA

Bernat Olle
Vedanta Biosciences
Cambridge, MA

Stephen J. Farr PhD
Zogenix, Inc.
Emeryville, CA

Pieter Boelhouwer JD
RA Capital Management, LP
Boston, MA

Harith Rajagoplan MD, PhD
Fractyl Health
Lexington, MA

Patrick Heron
Frazier Life Sciences
Menlo Park, CA

Zach Scheiner, PhD
RA Capital Management, LP
Boston, MA

Michael D. Clayman, MD
Flexion Therapeutics, Inc.
Burlington, MA

Jeffrey M. Solomon
Cowen Inc.
New York, NY

Jyoti Chauhan
Landos Biopharma Inc.
Blacksburg, VA

Anurag Kondapalli
RA Capital Management, LP
Boston, MA

Jake Simson, PhD
RA Capital Management, LP
Boston, MA

Marina Udier
Nouscom AG
Basel, Switzerland

JP Sommandossi
Atea Pharmaceuticals
Boston, MA

Fredrik Wiklund
Bright Peak Therapeutics
San Diego, CA

Tomer Kariv
Pontifax
Israel/UK

Laurie Halloran, BSN, MS
Halloran Consulting Group, Inc.
Boston, MA

Adam Rosenberg
Ambagon Therapeutics
San Francisco, CA

Bob Ward
OncoSec Immunotherapies
Princeton, NJ

Andrew Levin, MD, PhD
RA Capital Management, LP
Boston, MA

Maria Koehler MD, PhD
Repare Therapeutics
Cambridge, MA

Mark Corrigan MD
Exacis Biotherapeutics
Boston, MA

Laura Tadvalkar, PhD
RA Capital Management, LP
Boston, MA

James Mackay
Aristea Therapeutics
San Diego, CA

Zachary Hornby
Boundless Bio, Inc.
San Diego, CA

Matthew Hammond, PhD
RA Capital Management, LP
Boston, MA

Ali Behbahani
New Enterprise Associates
Washington DC

Branden B. Muhl
B Group Capital
Dallas, TX

Paul Sekhri
eGenesis, Inc.
New York, NY

Adi Hoess
Affimed NV
Heidelberg, Germany

Peter Greenleaf
Aurinia Pharmaceuticals
Rockville, MD

Michael Kauffman MD, PhD
Verastem
Newton, MA

Rosana Kapeller
ROME Therapeutics
Cambridge, MA

Zach Collins
Mission Biocapital
San Francisco, CA

Llew Keltner, MD, PhD
Light Sciences Oncology
Portland, OR

Christoph Westphal
Longwood Fund
Boston, MA

Roger J Pomerantz MD, FACP
ContraFect
New York, NY

Francesco Draetta
Omega Funds
Boston, MA

Bob Linke
Osmol Therapeutics, Inc.
New Haven, CT

Taylor Schreiber MD, PhD
Shattuck Labs, Inc.
Durham, NC

H. Stewart Parker
Parker BioConsulting
Chapel Hill NC

John P. Butler
Akebia Therapeutics
Cambridge, MA

James N. Campbell, MD, FAANS
Centrexion Therapeutics
Baltimore, MD

Russell Cox
Epirium Bio
San Diego, CA

Erich Scheller, PhD
RA Capital Management, LP
Boston, MA

Joseph Edelman
Perceptive Advisors
New York, NY

Derek DiRocco, PhD
RA Capital Management, LP
Boston, MA

David H. Crean
Coast BioVentures
San Diego, CA

Matt Cohen, PhD
Osage University Partners, LP
Bala Cynwyd, PA

Jeremy P. Springhorn, PhD
Nido Biosciences
Cambridge, MA

Peter Strumph
Parvus Therapeutics
San Francisco, CA

Jon Soderstrom, PhD
Yale University
New Haven, CT

Tess Cameron
RA Capital Management, LP
Boston, MA

Scott M. Rocklage
5AM Ventures
Boston, MA

Kevin Kimberlin
Spencer Trask & Co
Greenwich, CT

Laura Stoppel, PhD
RA Capital Management, LP
Boston, MA

Scott Kellen
DiaMedica Therapeutics Inc.
Minneapolis, MN

Bassil Dahiyat
Xencor
Monrovia, CA

Pratik Shah, PhD
Design Therapeutics
San Diego, CA

Jason Gardner
Magenta Therapeutics
Cambridge, MA

John F. Crowley
Amicus Therapeutics, Inc.
Philadelphia, PA

Brad Loncar
Loncar Investments
Lenexa, KS

Armando Anido
Zynerba Pharmaceuticals
Devon, PA

Joshua T. Brumm
Dyne Therapeutics
Waltham, MA

Dennis Purcell
Aisling Capital
New York City, NY

Walter H. Moos
Pandect Bioventures
South San Francisco, CA

Sandip Agarwala
Longitude Capital
Greenwich, CT

Reza Halse, PhD
RA Capital Management, LP
Boston, MA

John Tucker
scPharma
Burlington, MA

Randy Mitchell
Alyeska Investment Group
Chicago, IL

Adam Keeney
NodThera
Lexington, MA

Nancy Simonian
Syros Pharmaceuticals
Cambridge, MA

Ronald C Renaud Jr.
Translate Bio
Lexington, MA

Jeremy Bender, PhD
Day One Biopharmaceuticals, Inc.
South San Francisco, CA

Kate Moreau, PhD
RA Capital Management, LP
Boston, MA

Travis Wilson
Gurnet Point
Cambridge MA

Jeffrey H. Knapp
DNAtrix, Inc.
Houston, TX

Mike Derkacz
Braeburn
Plymouth Meeting, PA

Jeff Kindler
Centrexion Therapeutics
Boston, MA

Richard W. Pascoe
Histogen Inc.
San Diego, CA

Douglas Ingram
Sarepta Therapeutics
Cambridge, MA

Jason Lin
TwoThree Capital
Toronto, ON

Jason Bhardwaj
Follica, Inc.
Boston, MA

David de Graaf, PhD
Abcuro, Inc.
Newton, MA

John Neis
Venture Investors
Madison, WI

Wesley M. Jackson
Valitor
Berkeley, CA

Rich Aldrich
Longwood Fund
Boston, MA

Peter Rubin
No Patient Left Behind (NPLB)
Washington, DC

Adam Simpson
Icosavax, Inc.
Seattle, WA

Douglas M Fambrough
Dicerna Pharmaceuticals, Inc.
Lexington, MA

Shuo Zhang
AuGC Partners
Belmont, CA

Keith Murphy
Viscient Biosciences
San Diego, CA

Neil Warma
I-Mab Biopharma U.S.
San Diego, CA

Steve Elms
Aisling Capital
New York, NY

Jeffrey Herz, PhD
Algomedix, Inc.
Mill Creek, WA

Jeb Keiper
Nimbus Therapeutics
Cambridge, MA

Brent Ahrens
Canaan Partners
Menlo Park, CA

Wendell Wierenga, PhD
Chairman, Crinetics
San Diego, CA

Ken Takanashi
SNBL Ltd.
Tokyo, Japan

Misha Petkevich, DPhil
V2M Capital LLC
West Palm Beach, FL

Josh Mandel-Brehm
CAMP4 Therapeutics
Cambridge, MA

Chen Yu, MD, MBA
TCG Crossover
Palo Alto, CA

Jason Bonadio, MD
Alera Partners
Greenwich, CT

David Socks
HilleVax, Inc.
Boston, MA

Aaron Royston
venBio Partners
San Francisco, CA

Dillon Hoover
CASTLEARK MANAGEMENT, LLC
Chicago, IL

Art Pappas
Pappas Capital, LLC
Research Triangle Park, NC

Carmine Stengone
Pipeline Therapeutics
San Diego, CA

Laura A Brege
Acadia Pharmaceuticals
San Diego, CA

Jonathan Rourke
MitraSpan
Belmont, MA

Joseph Leveque, MD
Mirati Therapeutics
San Diego, CA

Evan Markegard
AuGC Partners LLC
Belmont, CA

David J. Woodhouse, PhD
NGM Biopharmaceuticals, Inc.
South San Francisco, CA

Rachael Nokes
scPharmaceuticals Inc.
Burlington, MA

Joseph Sarret
CohBar, Inc.
Menlo Park, CA

Bharat Chowrira, PhD, JD
PureTech Health
Boston, MA

Scott Harris
Cleave Therapeutics, Inc.
San Francisco, CA

Pearl Freier
Cambridge BioPartners, Inc.
Cambridge, MA

Joao Siffert
Design Therapeutics
San Diego, CA

Rick Pauls
DiaMedica Therapeutics
Minneapolis, MN

Catherine Stehman-Breen, MD
Chroma Medicine
Cambridge, MA

Michael Hassman
scPharmaceuticals Inc.
Burlington, MA

Joseph Bolen, PhD
PureTech Health
Boston, MA

Jacob Chacko, MD
ORIC Pharmaceuticals
South San Francisco, CA

Catherine Pearce, DHSc, MBA
CinCor Pharma Inc.
Cincinnati, OH

Justin R. Thompson
CinCor Pharma, Inc.
Cincinnati, OH

Albert Seymour, PhD
Homology Medicines, Inc.
Bedford, MA

Alyssa Larson, PhD
RA Capital Management, LP
Boston, MA

Neil Exter
Third Rock Ventures
Boston, MA

Chip Clark
Genocea Biosciences, Inc.
Cambridge, MA

William E. Rote, PhD
Travere Therapeutics
San Diego, CA

June H. Lee, MD
Esker Therapeutics
San Francisco, CA

Jonathan Piazza
Silverback Therapeutics
Seattle, WA

Cristina Ghenoiu, PhD
RA Capital Management, LP
Boston, MA

Adrian Gottschalk
Foghorn Therapeutics
Cambridge, MA

Will Brown
Altimune, Inc.
Gaithersburg, Maryland

Daniel E. Rosan
Synlogic Therapeutics
Cambridge, MA

Adrian (Ad) Rawcliffe
Adaptimmune
Philadelphia, PA

Emily Drabant Conley, PhD
Federation Bio
South San Francisco, CA

Steven Burke, MD
Akebia Therapeutics
Cambridge, MA

Richard Gaster, MD, PhD
venBio Partners
San Francisco, CA

Daniel Bensen
Tyra Biosciences, Inc.
Carlsbad, CA

John L. LaMattina
PureTech Hhealth
Stonington, CT

Nathaniel Brooks Horwitz
RA Capital Management, LP
Boston, MA

Jason Rhodes
Atlas Venture
Boston, MA

Lee D. Cooper
Leaps by Bayer
Cambridge, MA

Otello Stampacchia
Omega Funds
Boston, MA

Ankit Mahadevia, MD
Spero Therapeutics
Cambridge, MA

Brian Rosenberger
Zynerba Pharmaceuticals
Devon, PA

Kristina Burow
ARCH Venture Partners
Chicago, IL

Philip Astley-Sparke
Replimune Inc
Boston, MA

Faheem Hasnain
Gossamer Bio
San Diego, CA

Timothy P. Walbert
Horizon Therapeutics
Deerfield, IL

Stan Wang, MD, PhD
Thymune Therapeutics
Cambridge, MA

Rohan Palekar
89bio Inc.
San Francisco, CA

Nancy Lurker
EyePoint Pharmaceuticals
Watertown, MA

Ron Hunt
New Leaf Venture Partners
New York, NY

Ivor Royston, MD
Viracta Therapeutics
Cardiff, CA

Peter Parker
Mission BioCapital
Cambridge, MA

Todd Krueger
AOBiome Therapeutics
Cambridge, MA

Paulina Hill
Omega Funds
Boston, MA

Ari Zweiman
683 Capital Management LLC
New York, NY

Mark Leuchtenberger
Aleta Biotherapeutics
Natick, MA

Mike Sherman
Chimerix
Durham, North Carolina

CJ Sylvester
Manulife
Boston, MA

Ephraim Heller
SynAgile Corporation
Wilson, WY

Rebecca Lucia, CFA
5AM Ventures
San Francisco, CA

Paul Johnson
Braeburn
Plymouth Meeting, PA

Valerie Daggett, PhD
AltPep
Seattle, WA

W. Eddie Martucci, PhD
Akili Interactive Labs
Boston, MA

Mike Powell
Omega Funds
Boston, MA

Steve Dickman
CBT Advisors
Cambridge, MA

Fouad Azzam, PhD
Life Sciences Partners
Waltham, MA

Fred Aslan, MD
Artiva Biosciences
San Diego, CA

Ray Debbane
Invus
New York, NY

Habib Dable
Accelaron Pharma
Cambridge, MA

Michael A. Schrader
Vaxess Technologies, Inc.
Cambridge, MA

Philippe Amouyal
Invus
Miami, FL

David V. Goedel, PhD
Tenaya Therapeutics
San Francisco, CA

David Grayzel, MD
Atlas Venture
Boston, MA

Khalil Barrage
Invus
New York, NY

Steven Gillis
ARCH Venture Partners
Seattle, WA

Kris Jenner
Rock Springs Capital
Baltimore, MD

Bertrand Georges
Altimune Inc.
Gaithersburg, MD

Carl L. Hansen, PhD
AbCellera
Vancouver, BC Canada

David Kroin
Deep Track Capital
Greenwich, CT

Thomas E Darcy
Viracta Therapeutics, Inc.
Cardiff, CA

Adam M. Koppel
Bain Capital Life Sciences
Boston, MA

Vicente Anido, PhD
Aerie Pharmaceuticals, Inc
Durham, NC

Sen Sundaram
Terns Pharmaceuticals
Foster City, CA

Raju Kucherlapati
Harvard Medical School
Boston, MA

Aaron Davis
Boxer Capital
San Diego, CA

Greg Mayes
Antios Therapeutics
Mendham, NJ

Jonathan Kipnis
Washington University in St. Louis
St. Louis, MO

Evan Loh, MD
Paratek Pharmaceuticals
Boston, MA

Barry Quart, PharmD
Heron Therapeutics
San Diego, CA

Brian S. Kim, MD, MTR, FAAD
Washington University School of
Medicine; St. Louis, MO

Stephen Hurly
LAVA Therapeutics
Philadelphia, PA

Clay B. Thorp
Hatteras Venture Partners
Durham, NC

Norbert Bischofberger
Kronos Bio
San Mateo, CA

Jerry Cahill
Boomer Esiason Foundation
New York, NY

David Hirsch
Longitude Capital
Boston, MA

Angie YouPhD
Amunix Pharmaceuticals
South San Francisco, CA

Dave Madden
River 2 and 3 Renal Corps
New York, NY

Evan Greif
Bain Capital Life Sciences
Boston, MA

Kevin Bitterman
Atlas Venture
Cambridge, MA

Robert L. Hudkins
Tyra Bioscience
Carlsbad, CA

Jeffrey Bluestone, PhD
Sonoma Biotherapeutics
South San Francisco, CA

Adam Muzikant, PhD
Flexion Therapeutics
Burlington, MA

Emily Schaller
Rock CF Foundation
Detroit, MI

William S. Slattery
Deerfield Management
New York, NY

Daniel Vitt
Immunic Therapeutics
New York City, NY

Khrystal K Davis, JD
Texas Rare Alliance
Austin, TX

Jim Sullivan, PhD
Vanqua Bio
Chicago, IL

Hillary Theakston
Clarity
San Diego, CA

Noah L. Rosenberg, MD
Travere Therapeutics
San Diego, CA

Galya Blachman
5AM Ventures
San Francisco, CA

Deborah Palestrant
5AM Ventures
Boston, MA

Barry Labinger
Checkmate Pharmaceuticals
Cambridge, MA

Roderick Wong, MD
RTW Investments
New York, NY

Vasudev Bailey, PhD
Artis Ventures
San Francisco

Chris Garabedian
Perceptive Advisors
Boston, MA

Jose Ochoa
Altimmune
Gaithersburg, MD

Lloyd M. Segal
Repare Therapeutics Inc.
Cambridge, MA

Ansbert Gadicke
MPM Capital
Cambridge, MA

Robert Adelman, MD
venBio
San Francisco

Michael Nolan
Freenome
South San Francisco, CA

Peter Wirth
Quan Capital Management
Boston, MA

Michelle Ho
5AM Ventures
San Francisco, CA

Bong Koh, MD
Venrock
New York, NY

Bruce Booth
Atlas Venture
Boston MA

Albert Gianchetti
XyloCor Therapeutics
Malvern, PA

Peter Smith
Remix Therapeutics
Cambridge, MA

John E. Osborn
BioVentures Investors
Wellesley, MA

Sean McCarthy
CytomX Therapeutics
South San Francisco, CA

Jonathan Lim, MD
Erasca
San Diego, CA

Josh Richardson
Longitude Capital
Boston, MA

Kevin Pyun
Dellora Investments LP
Greenwich, CT

Pascal Touchon
Atara Biotherapeutics
San Francisco, CA

Robert Blazej, PhD
MBC Biolabs
San Francisco, CA

Samuel L Murphy, PhD
Salubris Biotherapeutics
Cambridge, MA

Aaron Hakim, MD
Deep Track Capital
Boston, MA

Mark Simon
Torreya Partners
New York, NY

James Brush, MD
Frazier Healthcare Partners
Menlo Park, CA

Thomas Malley
Mossrock Capital, LLC
Englewood, CO

Douglas Fisher, MD
InterWest Partners
Menlo Park, CA

Daniel Koller
BB Biotech AG
Schaffhausen, Switzerland

Sanjiv Patel
Relay Therapeutics
Boston, MA

Ryan Lane
Empery Asset Management LP
New York, NY

Sandy Mong MD
Atlas Venture
Boston, MA

James Blair
Domain Associates LLC
Princeton, NJ

Joanne Kotz, PhD
Jnana Therapeutics
Boston, MA

Allen Conger
NeuroMedica
Mt. Pleasant, SC

Michael Keyoung, MD, PhD
CBC Group
New York, NY

Seth Rotberg, MNM
Our Odyssey
Chicago, IL

Michael S. Weiss
TG Therapeutics
Boca Raton, FL

Bala Venkataraman
Avego Management
Alpharetta, GA

Stan Erck
Novavax
Gaithersburg, MD

Harris Weber
Bain Capital
Boston, MA

Gerard Smith
Deep Track Capital
Greenwich, CT

Michael Gladstone
Atlas Venture
Cambridge, MA

Axel Hoos
Scorpion Therapeutics
Boston, MA

Vincent S. Mosca
Ditch Plains Capital Management
Manhasset, NY

Colin Wang
6 Dimensions Capital
Cambridge, MA

Patrick Nosker, PhD
Affinity Asset Advisors, LLC
New York, NY

Fred Dotzler
De Novo Ventures
Saratoga, CA

Dan Janney
Alta Partners
San Francisco, CA

Michael J. Hearle
Clough Capital Partners
Boston, MA

Doug Roeder
Delphi Ventures
San Mateo, CA

David Allison
5AM Ventures
San Francisco, CA

Wende Hutton
Canaan Partners
Menlo Park CA

Robert F. Johnston
Johnston Associates, Inc.
South Hamilton, MA

Albert Cha
Frazier Healthcare Partners
Menlo Park, CA

Marc W. Elia
M28 Capital Management
Stamford, CT

Thomas A. Romero
Capital Research Partners & Co.
Norwalk, CT

Laurence Blumberg, MD
Arch Oncology
Brisbane, CA

Bryan Roberts
Venrock
Palo Alto, CA

Jonathan Root, MD
U.S. Venture Partners
Menlo Park, CA

Gary Stern
Eagle Health Investments
Greenwich, CT

Lazar Dimitrov, PhD
Day One Biopharmaceuticals
South San Francisco, CA

Andrew Oberwager MD
Machaon Capital Managemnt LP
Stamford, CT

Benjamin Young
Gray's Creek Capital Partners
Westport, CT

Julie Papanek Grant
Canaan
Menlo Park, CA

Owen Smith, MSc, CPFA
4BIO Capital
London, UK

Dr. Michael Fischer
Medical Strategy - Investmentmanager
Munich, Germany

Dmitry A. Kuzmin, PhD ,FRSB
4BIO Capital LLP
London, U.K.

Matt Renna
Westfield Capital Management
Boston, MA

Thilo Schroeder
Nextech Invest
Zurich, CH

Torbjorn Bjerke, MD
Arctic Asset Management
Stockholm, Sweden

Nicole Vitullo
Domain Associates, LLC
Princeton, NJ

Chris Varma, PhD
Frontier Medicines
South San Francisco, CA

Francis Parnell, MD
Parnell Pharmaceuticals Inc
San Rafael, CA

James Sapirstein
AzurRx BioPharma
Boca Raton, FL

Jay M. Short, PhD
BioAtla, Inc.
San Diego, CA

Jeff Livingstone
Igia Pharmaceuticals
Franklin, MA

Laurie Stelzer
Arena Pharmaceuticals
San Diego, CA

Thomas P. Mathers
Allievex Corporation
Marblehead, MA

Charles M. Baum, MD, PhD
Mirati Therapeutics Inc
San Diego, CA

Bill Newell
Sutro Biopharma, Inc.
South San Francisco, CA

Rami Levin
Saniona
Waltham, MA

Rick E. Winningham
Theravance Biopharma
South San Francisco, CA

Barry Simon, M.D.
ImmunityBio
San Diego, CA

Jigar Raythatha
Constellation Pharmaceuticals, Inc.
Cambridge, MA

*** Diseases that companies affiliated with signatories are working to prevent, treat, or cure:**

ADHD, ALS, Alzheimer's, Amyloid diseases, Anemia, ARDS, Autism, Autoimmune Disorders, Benign Prostatic Hyperplasia, Blindness, Breast Cancer, Chemotherapy Induced Peripheral Neuropathy and Chemotherapy Induced Cognitive Impairment, Chronic Hepatitis B, Chronic Lymphocytic Leukemia, Chronic Pain, Cognitive Injuries, Colorectal Cancer, Complement Disorders, COVID, Dementia, DM1, DMD, Enteric Hyperoxaluria, Fragile X syndrome, FSGS, FSHD, Gout, Heart Failure, Huntington's Diseases, Idiopathic Pulmonary Fibrosis, IgA nephropathy, Infectious Disease, Inflammatory Bowel Disease, Influenza, Long COVID, Lung Cancer, Lupus, Major Depressive Disorder, Melanoma, MLD, MPS2, Multiple Sclerosis, NASH, NMOSD, Non-Hodgkin Lymphoma, Obesity, Opioid Use Disorder, Osteoarthritis, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Parkinson's Psychosis, Pediatric Leukemias, Pediatric low grade glioma, PKU, Post-surgical Pain, Primary Biliary Cholangitis, Prostate Cancer, Pulmonary Arterial Hypertension, Rare Epilepsies, Renal Cancer, Retinal eye diseases, Rhatt's Syndrome, Stroke, Type 1 Diabetes, Type 2 Diabetes, Uterine Cancer, and many other diseases.

***The appended signatures do not necessarily reflect the policy or position of any agency, organization, employer, or company with which the signatories are affiliated.*

CC: House Energy and Commerce Committee Chair Pallone and Ranking Member McMorris Rodgers
House Ways and Means Committee Chair Neal and Ranking Member Brady
Senate Finance Chair Wyden and Ranking Member Crapo
Senate Health, Education, Labor, and Pensions Chair Murray and Ranking Member Burr

To join us in signing this letter, [please click here](#) and you'll be asked to enter your Name, Affiliation, City, State. We update this letter with signatories periodically, so your name won't show up right away.